Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


8th World Congress on Virology

San Antonio, USA

Maduike C O Ezeibe

Maduike C O Ezeibe

Michael Okpara University of Agriculture Umudike, Nigeria

Title: Medicinal synthetic aluminum-magnesium silicate [Al4(SiO4)3+3Mg2SiO4→2Al2Mg3(SiO4)3] effective treatment for HIV/AIDS


Biography: Maduike C O Ezeibe


Small size (110 nm) of the Human immunodeficiency virus (HIV) is what allows it access across physiological barriers, to get to the sanctuary cells in brain, bone marrow and testes where antiretroviral medicines (bigger molecules) have no access to it. Since the infection also depopulates lymphocytes (AIDS), nothing was left to terminate it. So, HIV/AIDS has been incurable. However, platelets (Nanoparticles) of molecules of aluminum-magnesium silicate (AMS) are smaller (0.96 nm thick). Edges of the nanoparticles are positively charged and their surfaces negatively charged while HIV is positively charged and infected cells, negatively charged. As nanoparticles AMS-platelets have access to all organs/tissues to bond their surfaces onto HIV-particles and their edges onto HIV-infected cells (including the sanctuary cells). They destroy the infected cells by the mechanism AMS traditionally disintegrates drug-capsules, so that hidden infections are unmasked. When 100% of the viral infection is mopped out, it terminates. For clinical trial of Medicinal synthetic aluminum-magnesium silicate (MSAMS, Antivirt®), 10 HIV/AIDS patients were treated daily, with MSAMS (50 mg/kg), MSAMS-stabilized ampicillin trihydrate (7.5 mg/kg) and immunace extra-protection® (1 tablet) for one month and then, for 10 months with only MSAMS and the immune stimulants. They were tested, monthly, for viral loads (VL) and CD4-lymphocytes counts (CD4). When their VL became undetectable they were tested for HIV confirmation. Their mean-VL increased (P=0.020) from 1820.30±868.75 to 2855.90±960.98 before reducing (P=0.0.030) to: 1565.20±743.17; 759.20±473.65; 345.50±115.012; 192.80±97.40; 95.00±55.80; 37.40±26.46 and <20/ml (undetectable: 17.50±16.88; 8.10 and 0.00±0.00). Their mean-CD4 reduced (P=0.008) from 496.80±194.39 to 263.90±149.26 before improving (P=0.001) to: 507.90±133.19; 692.70±113.34; 840.20±139.41; 1007.30±163.50 and >1500/ml (normal maximum: 1537.10±302.10; 1924.60±247.45; 2707.00±837.87). Three patients recovered after 8 months treatment, 2 after 9 months and 5 after 10 months. The Antivirt®-immune stimulants regimen terminated HIV-infection and repopulated lymphocytes. So, it is an effective treatment for HIV/AIDS.